INVESTMENT (Details Narrative) - USD ($) |
3 Months Ended | 9 Months Ended | |
|---|---|---|---|
Mar. 12, 2021 |
Sep. 30, 2021 |
Sep. 30, 2021 |
|
| Defined Benefit Plan Disclosure [Line Items] | |||
| Aggregrate investment | $ 6,000,000 | $ 6,000,000 | |
| Equity investment | 5,000,000 | 5,000,000 | |
| Convertable note investment | 1,000,000 | 1,000,000 | |
| Iliad [Member] | |||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Aggregrate investment | 6,000,000 | 6,000,000 | |
| Equity investment | 5,000,000 | 5,000,000 | |
| Equity investment - net loss | $ 186,000 | $ 632,000 | |
| Iliad [Member] | Class C Units [Member] | |||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Ownership percentage not fully diluted | 9.50% | 9.50% | |
| Ownership percentage fully diluted | 7.30% | 7.30% | |
| I Liad Biotechnologies L L C [Member] | |||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Additional convertable note investment | $ 1,000,000 | ||
| Maximum convertible debt offering | $ 23,500,000 | ||
| Interest rate | 6.00% | ||
| Notes conversion, description | The Notes are required to be converted into a Qualified Financing (minimum financing of $15 million) at the lesser of (i) 80% of the price paid per unit in such offering or (ii) a price based on an enterprise value of $176,000,000. In addition, the Notes shall convert in the event of a merger at the lower of an enterprise value of $176,000,000 or the stated valuation of ILiAD in the merger transaction |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. No definition available.
|
| X | ||||||||||
- Definition The average effective interest rate during the reporting period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Sum of the carrying amounts as of the balance sheet date of all investments. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of investments, and noncurrent assets classified as other. No definition available.
|
| X | ||||||||||
- Definition The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|